Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalent Pharma Solutions has signed a supply agreement with Vivus to supply Qsymia capsules, a proprietary combination phentermine and extended-release topiramate.
Subscribe to our email newsletter
Catalent Modified Release Technologies president Ian Muir said Catalent is pleased to have partnered with VIVUS to develop Qsymia and look forward to a long and successful relationship.
"As a combination therapy with two active ingredients that needed to be formulated and delivered in a controlled release dosage form, Qsymia presented unique formulation and drug delivery challenges,” Muir added.
Vivus president Peter Tam said the company has completed a long-term commercial supply agreement with Catalent to ensure the reliable on-going supply of Qsymia.
FDA has recently approved Qsymia as the first once-daily combination treatment for chronic weight management in adults who are obese or overweight with a weight-related co-morbidity.